<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02118831</url>
  </required_header>
  <id_info>
    <org_study_id>ML28032</org_study_id>
    <nct_id>NCT02118831</nct_id>
  </id_info>
  <brief_title>Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF</brief_title>
  <official_title>Systemic Pharmacokinetics Following Intravitreal Injections of Ranibizumab, Bevacizumab or Aflibercept in Patients With Neovascular Age-related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>California Retina Consultants</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>California Retina Consultants</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparable data for bevacizumab and aflibercept are lacking, as are studies comparing the
      systemic levels of ranibizumab, bevacizumab, and aflibercept and their relative effects on
      circulating vascular endothelial growth factor. In the present prospective study, the
      investigators evaluated serum drug levels and plasma free vascular endothelial growth factor
      (VEGF) levels in patients with neovascular age-related macular degeneration following
      intravitreal injections of ranibizumab, bevacizumab and aflibercept.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Pharmacokinetics Following Treatment From 1st and 3rd Doses</measure>
    <time_frame>Up to 4 months</time_frame>
    <description>Maximum serum levels of ranibizumab, bevacizumab or aflibercept will be measured after the first and third injections, up to 28 days following each treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Minimum Serum Levels of Free Vascular Endothelial Growth Factor From Baseline to Month 4 (One Month After Last Treatment)</measure>
    <time_frame>baseline and month 4</time_frame>
    <description>Minimum serum levels of free vascular endothelial growth factor will be measured at baseline and at 4 months following treatment (one month after last treatment).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Age-related Macular Degeneration</condition>
  <condition>Diabetic Macular Edema</condition>
  <condition>Retinal Vein Occlusion</condition>
  <arm_group>
    <arm_group_label>Aflibercept Blood Sample Collection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Blood samples will be collected from patients receiving aflibercept following the first and third dose of standard care therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bevacizumab Blood Sample Collection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Blood samples will be collected from patients receiving bevacizumab following the first and third dose of standard care therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ranibizumab Blood Sample Collection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Blood samples will be collected from patients receiving ranibizumab following the first and third dose of standard care therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood Sample Collection</intervention_name>
    <description>Subjects will have their blood drawn for analysis following their first and third injections of anti-VEGF.</description>
    <arm_group_label>Aflibercept Blood Sample Collection</arm_group_label>
    <arm_group_label>Bevacizumab Blood Sample Collection</arm_group_label>
    <arm_group_label>Ranibizumab Blood Sample Collection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aflibercept</intervention_name>
    <description>an intravitreal injection of Aflibercept administered three times on a monthly basis.</description>
    <arm_group_label>Aflibercept Blood Sample Collection</arm_group_label>
    <other_name>Eylea</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>an intravitreal injection of Bevacizumab administered three times on a monthly basis.</description>
    <arm_group_label>Bevacizumab Blood Sample Collection</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <description>an intravitreal injection of Ranibizumab administered three times on a monthly basis.</description>
    <arm_group_label>Ranibizumab Blood Sample Collection</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to provide written informed consent for participation in this study

          -  Subjects with a diagnosis of neovascular age-related macular degeneration, diabetic
             macular edema, or retinal vein occlusion who are either treatment na√Øve or more than 4
             months out from a prior intravitreal anti-vascular endothelial growth factor injection

        Exclusion Criteria:

          -  Subjects unwilling to receive 3 monthly injections of anti-vascular endothelial growth
             factor as initial therapy

          -  Subjects who may need or have received systemic anti-vascular endothelial growth
             factor for oncology in the past year

          -  Subjects with history of another ocular disease other than neovascular age-related
             macular degeneration, diabetic macular edema, or retinal vein occlusion

          -  Subjects with history of vitrectomy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert L Avery, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>California Retina Consultants</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Melvin D Rabena, BS</last_name>
    <role>Study Director</role>
    <affiliation>California Retina Consultants</affiliation>
  </overall_official>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2014</study_first_submitted>
  <study_first_submitted_qc>April 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2014</study_first_posted>
  <results_first_submitted>January 27, 2016</results_first_submitted>
  <results_first_submitted_qc>April 13, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 19, 2016</results_first_posted>
  <last_update_submitted>April 13, 2016</last_update_submitted>
  <last_update_submitted_qc>April 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>macular degeneration</keyword>
  <keyword>diabetic macular edema</keyword>
  <keyword>vein occlusion</keyword>
  <keyword>vascular endothelial growth factor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>patients were recruited at a single private medical clinic between May of 2012 through October 2013</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Aflibercept</title>
          <description>Blood samples will be collected from patients receiving aflibercept following the first and third dose of standard care therapy.
Aflibercept: Subjects will receive intravitreal aflibercept as part of their routine medical care.</description>
        </group>
        <group group_id="P2">
          <title>Bevacizumab</title>
          <description>Blood samples will be collected from patients receiving bevacizumab following the first and third dose of standard care therapy.
Bevacizumab: Subjects will receive intravitreal bevacizumab as part of their routine medical care.</description>
        </group>
        <group group_id="P3">
          <title>Ranibizumab</title>
          <description>Blood samples will be collected from patients receiving ranibizumab following the first and third dose of standard care therapy.
Ranibizumab: Subjects will receive intravitreal ranibizumab injections as part of their routine medical care.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aflibercept</title>
          <description>Blood samples will be collected from patients receiving aflibercept following the first and third dose of standard care therapy.
Aflibercept: Subjects will receive intravitreal aflibercept as part of their routine medical care.</description>
        </group>
        <group group_id="B2">
          <title>Bevacizumab</title>
          <description>Blood samples will be collected from patients receiving bevacizumab following the first and third dose of standard care therapy.
Bevacizumab: Subjects will receive intravitreal bevacizumab as part of their routine medical care.</description>
        </group>
        <group group_id="B3">
          <title>Ranibizumab</title>
          <description>Blood samples will be collected from patients receiving ranibizumab following the first and third dose of standard care therapy.
Ranibizumab: Subjects will receive intravitreal ranibizumab injections as part of their routine medical care.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="20"/>
            <count group_id="B4" value="56"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75" spread="4"/>
                    <measurement group_id="B2" value="75" spread="3"/>
                    <measurement group_id="B3" value="77" spread="5"/>
                    <measurement group_id="B4" value="76" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serum Pharmacokinetics Following Treatment From 1st and 3rd Doses</title>
        <description>Maximum serum levels of ranibizumab, bevacizumab or aflibercept will be measured after the first and third injections, up to 28 days following each treatment.</description>
        <time_frame>Up to 4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aflibercept</title>
            <description>Blood samples will be collected from patients receiving aflibercept following the first and third dose of standard care therapy.
Aflibercept: Subjects will receive intravitreal aflibercept as part of their routine medical care.</description>
          </group>
          <group group_id="O2">
            <title>Bevacizumab</title>
            <description>Blood samples will be collected from patients receiving bevacizumab following the first and third dose of standard care therapy.
Bevacizumab: Subjects will receive intravitreal bevacizumab as part of their routine medical care.</description>
          </group>
          <group group_id="O3">
            <title>Ranibizumab</title>
            <description>Blood samples will be collected from patients receiving ranibizumab following the first and third dose of standard care therapy.
Ranibizumab: Subjects will receive intravitreal ranibizumab injections as part of their routine medical care.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Pharmacokinetics Following Treatment From 1st and 3rd Doses</title>
          <description>Maximum serum levels of ranibizumab, bevacizumab or aflibercept will be measured after the first and third injections, up to 28 days following each treatment.</description>
          <units>nM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>After 1st dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" spread="0.29"/>
                    <measurement group_id="O2" value="0.76" spread="0.31"/>
                    <measurement group_id="O3" value="0.11" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After 3rd dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58" spread="0.52"/>
                    <measurement group_id="O2" value="1.47" spread="0.55"/>
                    <measurement group_id="O3" value="0.07" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Minimum Serum Levels of Free Vascular Endothelial Growth Factor From Baseline to Month 4 (One Month After Last Treatment)</title>
        <description>Minimum serum levels of free vascular endothelial growth factor will be measured at baseline and at 4 months following treatment (one month after last treatment).</description>
        <time_frame>baseline and month 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aflibercept</title>
            <description>Blood samples will be collected from patients receiving aflibercept following the first and third dose of standard care therapy.
Aflibercept: Subjects will receive intravitreal aflibercept as part of their routine medical care.</description>
          </group>
          <group group_id="O2">
            <title>Bevacizumab</title>
            <description>Blood samples will be collected from patients receiving bevacizumab following the first and third dose of standard care therapy.
Bevacizumab: Subjects will receive intravitreal bevacizumab as part of their routine medical care.</description>
          </group>
          <group group_id="O3">
            <title>Ranibizumab</title>
            <description>Blood samples will be collected from patients receiving ranibizumab following the first and third dose of standard care therapy.
Ranibizumab: Subjects will receive intravitreal ranibizumab injections as part of their routine medical care.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Minimum Serum Levels of Free Vascular Endothelial Growth Factor From Baseline to Month 4 (One Month After Last Treatment)</title>
          <description>Minimum serum levels of free vascular endothelial growth factor will be measured at baseline and at 4 months following treatment (one month after last treatment).</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.2" lower_limit="15.3" upper_limit="23.1"/>
                    <measurement group_id="O2" value="22.5" lower_limit="17.3" upper_limit="27.6"/>
                    <measurement group_id="O3" value="17.0" lower_limit="11.6" upper_limit="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3" lower_limit="8.5" upper_limit="14.2"/>
                    <measurement group_id="O2" value="10.6" lower_limit="6.9" upper_limit="14.1"/>
                    <measurement group_id="O3" value="17.0" lower_limit="13.2" upper_limit="21.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Aflibercept</title>
          <description>Blood samples will be collected from patients receiving aflibercept following the first and third dose of standard care therapy.
Aflibercept: Subjects will receive intravitreal aflibercept as part of their routine medical care.</description>
        </group>
        <group group_id="E2">
          <title>Bevacizumab</title>
          <description>Blood samples will be collected from patients receiving bevacizumab following the first and third dose of standard care therapy.
Bevacizumab: Subjects will receive intravitreal bevacizumab as part of their routine medical care.</description>
        </group>
        <group group_id="E3">
          <title>Ranibizumab</title>
          <description>Blood samples will be collected from patients receiving ranibizumab following the first and third dose of standard care therapy.
Ranibizumab: Subjects will receive intravitreal ranibizumab injections as part of their routine medical care.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Research</name_or_title>
      <organization>California Retina Consultants</organization>
      <phone>8059631648 ext 3034</phone>
      <email>gabe@californiaretina.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

